DYNAMICS_Study

Treatment tested

• Ozanimod

  Sphingosine 1-phosphate receptor 5 modulator

Other measures (1)

Inclusion: - For RRMS patients: Age between 18 and 55 years (in line with phase III RCTs); - For RRMS patients:A diagnosis of RRMS according to the 2017 Revisions of the McDonald criteria; - For RRMS patients: RRMS patients starting treatment with ozanimod, according to European Medicines Agency (EMA) and Italian Medicine Agency (AIFA) criteria (if available at the moment of study initiation); - For RRMS patients: EDSS score =5.0 (in line with phase III RCTs); - For RRMS patients: Planned vaccinations completed prior to enrollment; - For RRMS patients: Provide informed consent signed for participation in the trial; - For RRMS patients: Female participants of child bearing potential and male participants whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the trial and for 3 months thereafter.* * NOTE where the use of effective contraception is a protocol requirement a section on Contraception and Pregnancy should be added to the safety reporting section with corresponding information in the Participant Information Sheet. - For HC subjects: Age between 18 and 55 years; - For HC subjects: Provide informed consent signed for participation in the trial. Exclusion: - For RRMS patients: Age <18 or >55 years; - For HC subjects: Age <18 or >55 years; - For HC subjects: Major medical illnesses including neurological, cardiac, renal, hepatic, orthopedic, or rheumatologic disorders; - For HC subjects: History of psychiatric or mood disorders, or of drug or alcohol abuse; - For HC subjects: MRI contraindications; - For HC subject: Female participant who is pregnant, lactating or planning pregnancy during the course of the trial (positive urine ß-subunit of HCG). - For RRMS patients: Contraindications to ozanimod treatment as reported by EMA and AIFA (if available) recommendations; - For RRMS patients: Major medical illnesses including neurological (apart MS), cardiac, renal, hepatic, orthopedic, or rheumatologic disorders; - For RRMS patients: History of psychiatric or mood disorders, or of drug or alcohol abuse; - For RRMS patients: MRI contraindications, including claustrophobia, pregnancy, breastfeeding or metal implants; - For RRMS patients: One or more symptomatic treatment(s) (e.g., antidepressants, myorelaxants, psychoactive drugs) started/modified within the 3 months before ozanimod start; - For RRMS patients: The participant has previously participated in any clinical trial of ozanimod; - For RRMS patients: The participant is accommodated in an institution because of a regulatory or legal order, is a prisoner, or is legally institutionalized; - For RRMS patients: Female participant who is pregnant, lactating or planning pregnancy during the course of the trial. (positive urine ß-subunit of human chorionic gonadotropin [HCG]).

The primary objective of this study is to evaluate the effects of ozanimod in RRMS patients in limiting the progression of brain neurodegenerative phenomena over the course of 2 years.